Skip to content

Pacific Biosciences of California PACB Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies

Revvity logo
RevvityRVTY

Segments

By segment

See full
Reportable Segment$0+100%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Pacific Biosciences of California (PACB) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of $0 in Q1 2026.
How has Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1 increased by 100.0% year-over-year, from -$18.7M to $0.
What is the long-term trend for Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Over 4 years (2021 to 2025), Pacific Biosciences of California's business combination contingent consideration arrangements change in amount of contingent consideration liability1 has grown at a 101.1% compound annual growth rate (CAGR), from $1.14M to -$18.7M.
What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
This represents the change in the fair value of liabilities related to earn-outs or other contingent payments promised to sellers in an acquisition. Fluctuations in this value reflect changes in the probability or expected amount of future payouts based on the acquired entity's performance. It provides insight into the accuracy of initial acquisition valuation models and the performance trajectory of acquired units.